More Than Four Cycles of Peptide-Based Radiation Therapy Was Safe and Extended Survival in Neuroendocrine Tumor Patients | Research

The takeaway

Extending peptide receptor radionuclide therapy beyond the standard 4 cycles was kidney-safe and associated with 20 months longer survival in neuroendocrine tumor patients.

20-month survival advantage
Patients receiving more than 4 PRRT cycles had median overall survival of 72.8 months vs 52.8 months for standard treatment, with comparable kidney safety

What the researchers found

In 637 neuroendocrine tumor patients, extending peptide receptor radionuclide therapy (PRRT) beyond the standard 4 cycles was safe and improved survival. The extended treatment group (>4 cycles, n=356) had significantly longer median overall survival (72.8 months) compared to the standard group (4 cycles, n=281, 52.8 months). Cox regression confirmed a 42% lower risk of death (HR 0.580, p<0.001) and 40% lower disease-specific mortality (HR 0.599, p<0.001) in the extended group. Kidney safety was comparable: mean post-treatment creatinine levels did not differ significantly (93.20 vs 89.30 μmol/L, p=0.364), and adverse renal events occurred in only 1.1% of extended vs 0.4% of standard patients.

Why it matters

PRRT uses radioactive peptides that bind to somatostatin receptors on neuroendocrine tumors to deliver targeted radiation. The standard protocol limits treatment to 4 cycles due to kidney safety concerns, but this large study shows that additional cycles are safe and provide a meaningful 20-month survival advantage — potentially changing treatment guidelines for patients whose tumors recur or progress.

The numbers in context

n=637 (281 standard, 356 extended) · median OS 72.8 vs 52.8 months · HR 0.580 (p<0.001) · DSS HR 0.599 (p<0.001) · creatinine 93.20 vs 89.30 μmol/L (p=0.364) · renal events 1.1% vs 0.4% · median follow-up 88.3 months

How the study worked

Retrospective analysis of 637 neuroendocrine tumor patients who received at least 4 PRRT cycles. Patients were divided into standard (4 cycles, n=281) and extended (>4 cycles, n=356) groups. Kidney function was assessed via creatinine levels and CTCAE grading. Survival was analyzed using Kaplan-Meier curves and Cox regression. Median follow-up was 88.3 months.

Who was studied

637 neuroendocrine tumor patients who received at least 4 cycles of peptide receptor radionuclide therapy

What this study cannot tell us

Retrospective study design with potential selection bias — patients receiving extended treatment may have been those with better performance status or more favorable disease biology. The study did not randomize patients to standard vs extended treatment. Specific PRRT agents and cumulative doses were not detailed in the abstract.

How to read the evidence

Large retrospective cohort study with 637 patients and nearly 7.5 years median follow-up. While the size and follow-up duration are strengths, the retrospective design and potential selection bias limit causal conclusions. A randomized trial would be needed to confirm the benefit.

When this study was published

Published in 2024, this study addresses a current clinical debate about PRRT treatment duration and provides timely evidence for practitioners making real-time treatment decisions.

The bigger picture

PRRT has become a cornerstone therapy for advanced neuroendocrine tumors since the NETTER-1 trial established the 4-cycle standard. This study challenges that limit and provides the largest evidence base for extended PRRT, potentially opening the door to more individualized, sustained peptide-based treatment for a cancer with few effective options.

Questions still open

Would a randomized controlled trial confirm the survival benefit of extended PRRT, or is selection bias inflating the results?
What is the optimal number of additional PRRT cycles beyond four — is there a point of diminishing returns?
Could newer kidney-protective strategies (like amino acid infusions) further improve the safety profile of extended PRRT?

Common questions

What is peptide receptor radionuclide therapy (PRRT)?

PRRT is a targeted cancer treatment where a radioactive atom is attached to a peptide (small protein) that binds to specific receptors on neuroendocrine tumor cells. When injected, the peptide carries radiation directly to the tumor while largely sparing normal tissues. The most common version uses a somatostatin analog peptide.

Why is kidney damage a concern with PRRT?

The kidneys filter the radioactive peptide from the blood, which exposes them to radiation. After multiple treatment cycles, this cumulative radiation exposure can damage kidney tissue. This study found that even with more than 4 cycles, kidney damage remained rare (1.1%), suggesting the risk has been overestimated.

Read the original research

Extended peptide receptor radionuclide therapy: evaluating nephrotoxicity and therapeutic effectiveness in neuroendocrine tumor patients receiving more than four treatment cycles.

European journal of nuclear medicine and molecular imaging, 51(4), 1136-1146

View on PubMed ↗Publisher’s paper ↗

Citation

Baum, Richard P; Fan, Xin; Jakobsson, Vivianne; Schuchardt, Christiane; Chen, Xiaoyuan; Yu, Fei; Zhang, Jingjing. (2024). Extended peptide receptor radionuclide therapy: evaluating nephrotoxicity and therapeutic effectiveness in neuroendocrine tumor patients receiving more than four treatment cycles.. European journal of nuclear medicine and molecular imaging, 51(4), 1136-1146. https://doi.org/10.1007/s00259-023-06544-2